01888nas a2200325   4500000000100000008004100001260001300042653002600055653001000081653002800091653001900119653003000138653003100168653001100199653001100210653001200221653001600233653002400249653001300273653001700286653002800303100001400331700001500345700001900360245009300379300001000472490000700482520105900489022001401548       1992                            d  c1992 Dec10aAcetylglucosaminidase10aAdult10aCross-Sectional Studies10aDrug Synergism10aDrug Therapy, Combination10aGlomerular Filtration Rate10aHumans10aKidney10aleprosy10aMiddle Aged10aProspective Studies10aRifampin10aStreptomycin10aTuberculosis, Pulmonary1 aKumar B D1 aPrasad C E1 aKrishnaswamy K00aDetection of rifampicin-induced nephrotoxicity by N-acetyl-3-D-glucosaminidase activity.  a424-70 v953 a<p>The objective of the present study was to assess renal damage, if any, by non-invasive technique, viz NAG activity in urine and GFR in patients on continuous and intermittent rifampicin therapy. Eighty-four tuberculosis patients for cross-sectional study and six subjects for longitudinal study on antitubercular therapy and ten patients on withdrawal of rifampicin participated in the investigation; 13 leprosy patients intermittently treated with rifampicin were also included. Twenty-seven normal subjects served as controls. Rifampicin on continuous use resulted in a progressive increase in enzymuria with no change in GFR. An additive toxic effect was obvious in patients receiving streptomycin; when the treatment was withdrawn the urinary NAG activity stabilized within 15-21 days. However, patients receiving rifampicin intermittently did not show any evidence of renal damage. The results suggest that there is a need for monitoring renal damage, particularly on antitubercular therapy, when nephrotoxic agents are administered together.</p>  a0022-5304